Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint, reductions in lesion growth rate, in the pivotal, global Phase 3 ...

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint, reductions ...

Five issued U.S. patents cover the combination of ImmunityBio’s IL-15 receptor agonist (NAI) with Bacillus Calmette-Guérin ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced an exclusive U.S. Development and ...

Sarah Pidgeon revealed she uses the Bioeffect EGF Serum, which contains retinol to help heal blemishes and calm skin redness.

Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal ...

Detailed price information for Bridgebio Pharma Inc (BBIO-Q) from The Globe and Mail including charting and trades.

Cabaletta Bio (CABA) remains a Buy: rese-cel trial catalysts, autoimmune upside, scalable manufacturing, and key risks like ...

Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the ...

Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable ...

There are also shampoos and scalp care products available which claim to promote healthy hair growth ...